Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Medically reviewed by Erika Prouty, PharmD Key Takeaways There are two types of complement 3 glomerulopathy: dense deposit ...

Medically reviewed by David Ozeri, MD Complement 3 glomerulopathy (C3G) is considered a very rare disease. With C3G, patients have issues with their immune system that cause kidney damage and symptoms ...

C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) are two rare kidney diseases. They’re both driven by activity of the complement system, which is a ...

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced it ...

The complement system is a key component of innate and adaptive immunity and therefore acts as a vital defense against invading pathogens. Deficiencies in the complement system are associated with ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

Dysfunction of the complement system plays an important role in the pathogenesis of renal diseases. Complement inhibitors, such as C5 inhibitors, have shown efficacy in clinical trials, but may no be ...